Fabrazyme® (agalsidase beta) – Expanded indication
March 12, 2021 - Sanofi announced the FDA approval of Fabrazyme (agalsidase beta), for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.
Download PDF
